POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Clinical trials for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) explained in plain language.
Never miss a new study
Get alerted when new POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) trials appear
Sign up with your email to follow new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug regimen could mean fewer shots for PCV patients
Disease control Recruiting nowThis study tests a higher dose of the drug aflibercept (8 mg) given on a personalized schedule to people with a specific eye condition called polypoidal choroidal vasculopathy (PCV), a type of wet macular degeneration. The goal is to see if this approach can safely extend the tim…
Matched conditions: POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Phase: PHASE3 • Sponsor: Yeungnam University College of Medicine • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New eye drug regimen aims to extend time between treatments for PCV patients
Disease control Recruiting nowThis study tests a personalized treat-and-extend schedule for faricimab in 50 people newly diagnosed with polypoidal choroidal vasculopathy (PCV), a type of wet age-related macular degeneration. The goal is to see if this approach can keep the disease under control while allowing…
Matched conditions: POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Phase: PHASE3 • Sponsor: Yeungnam University College of Medicine • Aim: Disease control
Last updated May 12, 2026 13:41 UTC